Clinical Trial Update: Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine [Phase 2]

View source ↗

Summary

A completed Phase 2 dose-ranging study evaluating a recombinant HPV 16/18 bivalent vaccine for cervical intraepithelial neoplasia and cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Intraepithelial Neoplasia

Drugs mentioned

• HPV-16/18 bivalent vaccine (recombinant human papillomavirus vaccine (types 16 and 18))

Snippet

Sponsor: Xiamen University | Conditions: Cervical Intraepithelial Neoplasia, Cervical Cancer | Phase 2 | Status: COMPLETED